Global Peptide Receptor Radionuclide Therapy (PRRT) Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Peptide Receptor Radionuclide Therapy (PRRT) market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Peptide Receptor Radionuclide Therapy (PRRT) include Aurobindo Pharma, Curium Pharmaceuticals, Lantheus, Mundipharma, Bayer and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide Receptor Radionuclide Therapy (PRRT), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Receptor Radionuclide Therapy (PRRT).
The Peptide Receptor Radionuclide Therapy (PRRT) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide Receptor Radionuclide Therapy (PRRT) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Company
Aurobindo Pharma
Curium Pharmaceuticals
Lantheus
Mundipharma
Bayer
Novartis
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Type
Midgut Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Foregut Neuroendocrine Tumor
Hindgut Neuroendocrine Tumor
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Receptor Radionuclide Therapy (PRRT) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Receptor Radionuclide Therapy (PRRT) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Receptor Radionuclide Therapy (PRRT).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Peptide Receptor Radionuclide Therapy (PRRT) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Peptide Receptor Radionuclide Therapy (PRRT) market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Peptide Receptor Radionuclide Therapy (PRRT) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Peptide Receptor Radionuclide Therapy (PRRT) include Aurobindo Pharma, Curium Pharmaceuticals, Lantheus, Mundipharma, Bayer and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide Receptor Radionuclide Therapy (PRRT), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Receptor Radionuclide Therapy (PRRT).
The Peptide Receptor Radionuclide Therapy (PRRT) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide Receptor Radionuclide Therapy (PRRT) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Company
Aurobindo Pharma
Curium Pharmaceuticals
Lantheus
Mundipharma
Bayer
Novartis
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Type
Midgut Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Foregut Neuroendocrine Tumor
Hindgut Neuroendocrine Tumor
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Peptide Receptor Radionuclide Therapy (PRRT) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Receptor Radionuclide Therapy (PRRT) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Receptor Radionuclide Therapy (PRRT) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Receptor Radionuclide Therapy (PRRT).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Peptide Receptor Radionuclide Therapy (PRRT) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
87 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2020-2031)
- 1.4.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2020-2025)
- 1.4.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Region (2026-2031)
- 1.5 Key Regions Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2020-2031)
- 1.5.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (2020-2031)
- 1.5.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (2020-2031)
- 1.5.4 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (2020-2031)
- 2 Peptide Receptor Radionuclide Therapy (PRRT) Market by Type
- 2.1 Type Introduction
- 2.1.1 Midgut Neuroendocrine Tumor
- 2.1.2 Gastroenteropancreatic Neuroendocrine Tumor
- 2.1.3 Foregut Neuroendocrine Tumor
- 2.1.4 Hindgut Neuroendocrine Tumor
- 2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Type
- 2.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Overview by Type (2020-2031)
- 2.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Forecasted by Type (2026-2031)
- 2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Regions
- 2.3.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Type (2020-2025)
- 3 Peptide Receptor Radionuclide Therapy (PRRT) Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital Pharmacies
- 3.1.2 Online Pharmacies
- 3.1.3 Retail Pharmacies
- 3.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Application
- 3.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Overview by Application (2020-2031)
- 3.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size Forecasted by Application (2026-2031)
- 3.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Regions
- 3.3.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 Peptide Receptor Radionuclide Therapy (PRRT) Industry Trends
- 4.2 Peptide Receptor Radionuclide Therapy (PRRT) Industry Drivers
- 4.3 Peptide Receptor Radionuclide Therapy (PRRT) Industry Opportunities and Challenges
- 4.4 Peptide Receptor Radionuclide Therapy (PRRT) Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by Peptide Receptor Radionuclide Therapy (PRRT) Revenue (2020-2025)
- 5.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Key Company Headquarters & Area Served
- 5.4 Global Peptide Receptor Radionuclide Therapy (PRRT) Company, Product Type & Application
- 5.5 Global Peptide Receptor Radionuclide Therapy (PRRT) Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Peptide Receptor Radionuclide Therapy (PRRT) Players Market Share by Revenue in 2024
- 5.6.3 2024 Peptide Receptor Radionuclide Therapy (PRRT) Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 Aurobindo Pharma
- 6.1.1 Aurobindo Pharma Comapny Information
- 6.1.2 Aurobindo Pharma Business Overview
- 6.1.3 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 6.1.5 Aurobindo Pharma Recent Developments
- 6.2 Curium Pharmaceuticals
- 6.2.1 Curium Pharmaceuticals Comapny Information
- 6.2.2 Curium Pharmaceuticals Business Overview
- 6.2.3 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 6.2.5 Curium Pharmaceuticals Recent Developments
- 6.3 Lantheus
- 6.3.1 Lantheus Comapny Information
- 6.3.2 Lantheus Business Overview
- 6.3.3 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 6.3.5 Lantheus Recent Developments
- 6.4 Mundipharma
- 6.4.1 Mundipharma Comapny Information
- 6.4.2 Mundipharma Business Overview
- 6.4.3 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 6.4.5 Mundipharma Recent Developments
- 6.5 Bayer
- 6.5.1 Bayer Comapny Information
- 6.5.2 Bayer Business Overview
- 6.5.3 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 6.5.5 Bayer Recent Developments
- 6.6 Novartis
- 6.6.1 Novartis Comapny Information
- 6.6.2 Novartis Business Overview
- 6.6.3 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
- 6.6.5 Novartis Recent Developments
- 7 North America
- 7.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2020-2025)
- 7.3 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2020-2025)
- 8.3 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2020-2025)
- 9.3 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2020-2025)
- 10.3 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size by Country (2020-2025)
- 11.3 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



